Clinical Trials Update – December 2021
December 2021 - In this summary, we have highlighted recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
December 2021 - In this summary, we have highlighted recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
Dr. David Josephy and Jim Hughes discuss clinical trials for GISTers and what you need to know.
Clinical Trials 101, a GISTory of Clinical Trials, & How to Talk to Your Medical Team about Clinical Trials Clinical trials are an essential tool of modern medicine. We have heard a lot about [...]
LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.
The mission of the Clinical Trials Transformation Initiative (CTTI) is to develop and drive the adoption of practices that will increase the quality and efficiency of clinical trials.
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.
Dr. Breelyn Wilky answering questions on a panel of GIST experts at Life Fest Miami, 2018. Colorado, Clinical Trials & Immunotherapy Dr. Wilky, Director of Sarcoma Translational Research at the University of [...]
How to Make 2/3 = 1 (100%) In a recent discussion about the frequency of mutations in GIST, we noted that the most common mutation is KIT exon 11, which makes up about 2/3 [...]